Early results show tumours shrinking or disappearing in around 67% of cases
You may have heard reports of a new ‘blockbuster’ drug for womb cancer called Mo-Rez. Early results show tumours shrinking or disappearing in around 67% of people with womb (endometrial) cancer in a clinical trial.
The treatment, called mocertatug rezetecan (Mo-Rez), is being developed by GSK and is part of a group of medicines known as antibody-drug conjugates (ADCs), designed to target cancer cells more directly while helping to limit damage to healthy cells.
In a study involving more than 200 people with gynaecological cancers, specifically womb and ovarian cancer, around 67% of people with womb cancer and 62% of people with ovarian cancer saw their tumours reduce. The results are from people whose cancer had returned or stopped responding to chemotherapy, where treatment options are currently limited.
The treatment is given as an intravenous infusion every three weeks. Most people were able to stay on treatment, with the most common side effects including nausea and low blood counts. Researchers described these as generally manageable.
At present, treatment options for womb cancer that has returned or stopped responding to chemotherapy are limited, so new approaches are urgently needed. Research into new treatments, including immunotherapy and targeted drugs such as Mo-Rez, is an important step forward.
Dr Eleanor Jones, Chair of Trustees at Peaches Womb Cancer Trust says:
Peaches Womb Cancer Trust is encouraged to see such a promising response in early trial results for mocertatug rezetecan (Mo-Rez). While these are early findings and further research is needed to understand how effective and safe this treatment is over time, developments like this offer real hope for people with advanced womb cancer, particularly those whose cancer has returned or stopped responding to chemotherapy.
As a charity supporting anyone living with and beyond womb cancer, we know this news will be welcomed by our community as a sign of progress, in an area where gynaecological cancers have historically received less research funding compared to other cancer types. We are pleased to see continued investment from GSK into the development of vital new treatments for womb cancer.
Because of these early results, GSK plans to move forward with larger, late-stage clinical trials, including studies specifically for womb cancer, starting over the next year. These studies will include people in the UK and other countries, with the aim of understanding more about how effective and safe the treatment is over time.
If successful, this research could lead to new treatment options for womb cancer in the future, particularly for those with more advanced disease or limited alternatives.
